|
1
|
Lortet TJ, Soerjomataram I, Ferlay J,
Rutherford M, Weiderpass E and Bray F: International trends in lung
cancer incidence by histological subtype: Adenocarcinoma
stabilizing in men but still increasing in women. Lung Cancer.
84:13–22. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang T, Nelson RA, Bogardus A and Grannis
FW Jr: Five-year lung cancer survival: Which advanced stage
nonsmall cell lung cancer patients attain long-term survival?
Cancer. 116:1518–1525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Deroo BJ and Korach KS: Estrogen receptors
and human disease. J Clin Invest. 6:561–570. 2006. View Article : Google Scholar
|
|
6
|
Donington JS and Colson YL: Sex and gender
differences in non-small cell lung cancer. Semin Thorac Cardiovasc
Surg. 23:137–145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meinhold CL, de González Berrington A,
Bowman ED, Brenner AV, Jones RT, Lacey JV Jr, Loffredo CA,
Perlmutter D, Schonfeld SJ, Trivers GE and Harris CC: Reproductive
and hormonal factors and the risk of nonsmall cell lung cancer. Int
J Cancer. 128:1404–1413. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheskis BJ, Greger JG, Nagpal S and
Freedman LP: Signaling by estrogens. J Cell Physiol. 213:610–617.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dubey S, Siegfried JM and Traynor AM:
Non-small-cell lung cancer and breast carcinoma: Chemotherapy and
beyond. Lancet Oncol. 7:416–424. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pietras RJ, Marquez DC, Chen HW, Tsai E,
Weinberg O and Fishbein M: Estrogen and growth factor receptor
interactions in human breast and non-small cell lung cancer cells.
Steroids. 70:372–381. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luksha L and Kublickiene K: The role of
estrogen receptor subtypes for vascular maintenance. Gynecol
Endocrinol. 25:82–95. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ullrich ND, Krust A, Collins P and MacLeod
KT: Genomic deletion of estrogen receptors ERalpha and ERbeta does
not alter estrogen-mediated inhibition of Ca2+ influx and
contraction in murine cardiomyocytes. Am J Physiol Heart Circ
Physiol. 294:H2421–H2427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Prossnitz ER, Arterburn JB, Smith HO,
Oprea TI, Sklar LA and Hathaway HJ: Estrogen signaling through the
transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol.
70:165–190. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mizukami Y: In vivo functions of
GPR30/GPER-1, a membrane receptor for estrogen: From discovery to
functions in vivo. Endocr J. 57:101–107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bologa CG, Revankar CM, Young SM, Edwards
BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck
NP, Sklar LA, et al: Virtual and biomolecular screening converge on
a selective agonist for GPR30. Nat Chem Biol. 2:207–212. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chan QK, Lam HM, Ng CF, Lee AY, Chan ES,
Ng HK, Ho SM and Lau KM: Activation of GPR30 inhibits the growth of
prostate cancer cells through sustained activation of Erk1/2,
c-jun/c-fos-dependent upregulation of p21 and induction of G(2)
cell-cycle arrest. Cell Death Differ. 17:1511–1523. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ariazi EA, Brailoiu E, Yerrum S, Shupp HA,
Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea
TI, et al: The G Protein-coupled receptor GPR30 inhibits
proliferation of estrogen receptor-positive breast cancer cells.
Cancer Res. 1:1184–1194. 2010. View Article : Google Scholar
|
|
18
|
Wang C, Lv X, Jiang C and Davis JS: The
putative G-protein coupled estrogen receptor agonist G-1 suppresses
proliferation of ovarian and breast cancer cells in a
GPER-independent manner. Am J Transl Res. 4:390–402.
2012.PubMed/NCBI
|
|
19
|
Tong L, Chuang CC, Wu S and Zuo L:
Reactive oxygen species in redox cancer therapy. Cancer Lett.
367:18–25. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kurt AH and Buyukafsar K: Vasoconstriction
induced by G1, a G-protein-coupled oestrogen receptor1 (GPER-1)
agonist, in the isolated perfused rat kidney. Eur J Pharmacol.
702:71–78. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pektas M, Kurt AH, Un I, Tiftik RN and
Buyukafsar K: Effects of 17β-estradiol and progesterone on the
production of adipokines in differentiating 3T3-L1 adipocytes: Role
of Rho-kinase. Cytokine. 72:130–134. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jala VR, Radde BN, Haribabu B and Klinge
CM: Enhanced expression of G-protein coupled estrogen receptor
(GPER/GPR30) in lung cancer. BMC Cancer. 28:612–624. 2012.
|
|
23
|
Ribble D, Goldstein NB, Norris DA and
Shellman YG: A simple technique for quantifying apoptosis in
96-well plates. BMC Biotechnol. 5:122005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aebi H: Catalase in vitro. Methods
Enzymol. 105:121–126. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
|
26
|
Fridovich I: Superoxide dismutase. Adv
Enzymol. 41:35–97. 1974.PubMed/NCBI
|
|
27
|
Levander OA, DeLoach DP, Morris VC and
Moser PB: Platelet glutathione peroxidase activity as an index of
selenium status in rats. J Nutr. 113:55–63. 1983.PubMed/NCBI
|
|
28
|
Griess JP: Comments on the discussion of
the HH. Weselsky and Benedict ‘on some azo compounds’. Ber Deutsch
Chem Ges. 12:426–428. 1879.(In German). View Article : Google Scholar
|
|
29
|
Cohen JJ: Apoptosis: The physiological
pathway of cell death. Hosp Pract (Off Ed). 15:35–43. 1993.
|
|
30
|
Wang C, Lv X, He C, Hua G, Tsai MY and
Davis JS: The G-protein-coupled estrogen receptor agonist G-1
suppresses proliferation of ovarian cancer cells by blocking
tubulin polymerization. Cell Death Dis. 4:e8692013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chan QK, Lam HM, Ng CF, Lee AY, Chan ES,
Ng HK, Ho SM and Lau KM: Activation of GPR30 inhibits the growth of
prostate cancer cells through sustained activation of Erk1/2,
c-jun/c-fos-dependent upregulation of p21 and induction of G(2)
cell-cycle arrest. Cell Death Differ. 17:1511–1523. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Young IS and Woodside JV: Antioxidants in
health and disease. J Clin Pathol. 54:176–186. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Khan MA, Tania M, Zhang DZ and Chen HC:
Antioxidant enzymes and cancer. Chin J Cancer Res. 22:87–92. 2010.
View Article : Google Scholar
|
|
34
|
Pallepati P and Averill-Bates DA:
Activation of ER stress and apoptosis by hydrogen peroxide in HeLa
cells: Protective role of mild heat preconditioning at 40°C.
Biochim Biophys Acta. 1813:1987–1999. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Giorgio M, Migliaccio E, Orsini F,
Paolucci D, Moroni M, Contursi C, Pelliccia G, Luzi L, Minucci S,
Marcaccio M, et al: Electron transfer between cytochrome c and
p66Shc generates reactive oxygen species that trigger mitochondrial
apoptosis. Cell. 122:221–233. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Benitez DA, Pozo-Guisado E,
Alvarez-Barrientos A, Fernandez-Salguero PM and Castellón EA:
Mechanisms involved in resveratrol-induced apoptosis and cell cycle
arrest in prostate cancer-derived cell lines. J Androl. 28:282–293.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Khan MA, Chen HC, Wan XX, Tania M, Xu AH,
Chen FZ and Zhang DZ: Regulatory effects of resveratrol on
antioxidant enzymes: A mechanism of growth inhibition and apoptosis
induction in cancer cells. Mol Cells. 35:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dong WH, Chen JC, He YL, Xu JJ and Mei YA:
Resveratrol inhibits K(v)2.2 currents through the estrogen receptor
GPR30-mediated PKC pathway. Am J Physiol Cell Physiol. 305:547–557.
2013. View Article : Google Scholar
|
|
39
|
Pacher P, Beckman JS and Liaudet L: Nitric
oxide and peroxynitrite in health and disease. Physiol Rev.
87:315–424. 2007. View Article : Google Scholar : PubMed/NCBI
|
